Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...

A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...

A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...

Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But without US foreign aid dollars, its delivery to millions worldwide is under ...

US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New ...

Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ:GILD)' Lenacapavir (LEN) for HIV prevention (PrEP) on or before its June 19 PDUFA date, a move that the bank believes could drive ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application submissions for lenacapavir for human immunodeficiency virus (HIV) prevention.

Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...

Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...